Nuclera, the biotechnology company enabling access to innovative protein technologies, today announced the publication of research conducted in collaboration with researchers at the University of Cambridge's Department of Biochemistry, demonstrating a rapid, cell-free approach utilizing proprietary nanodisc technology to produce challenging protein drug-targets for high-resolution structural analysis.